Why is the Fed hesitant on December rate cuts?
How did Nvidia calm AI bubble fears?
Why is Verizon cutting 13,000 jobs now?
What drove Walmart’s rising e-commerce sales?
How will Trump’s AI regulation affect states?
Why is Japan increasing foreign residency fees?
What impacts do rare-earth export shifts have?
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study
benzinga.com/news/health-care/25/11/48812391/alkermes-eyes-global-phase-3-trial-after-encouraging-data-from-sleep-disorder-study
Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2).
Narcolepsy type 2, also known as narcolepsy without cataplexy, is a sleep disorder characterized by…
This story appeared on benzinga.com, 2025-11-12 17:46:56.